Sfoglia per Rivista
Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial
2016-01-01 Krischke, M; Hempel, G; Voller, S; Andre, N; D'Incalci, M; Bisogno, G; Kopcke, W; Borowski, M; Herold, R; Boddy, Av; Boos, J
Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph plus acute leukemias
2009-01-01 Marangon, E; Citterio, M; Sala, F; Barisone, E; Lippi, Aa; Rizzari, C; Biondi, A; D'Incalci, M; Zucchetti, M
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib
2013-01-01 Zucchetti, M; Bonezzi, K; Frapolli, R; Sala, F; Borsotti, P; Zangarini, M; Cvitkovic, E; Noel, K; Ubezio, P; Giavazzi, R; D'Incalci, M; Taraboletti, G
The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma
2000-01-01 Fumagalli, L; Zucchetti, M; Parisi, I; Viganò, M G; Zecca, B; Careddu, A; D'Incalci, M; Lazzarin, A
Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)
1999-01-01 Sessa, C; Zucchetti, M; Ghielmini, M; Bauer, J; D'Incalci, M; de Jong, J; Naegele, H; Rossi, S; Pacciarini, Ma; Domenigoni, L; Cavalli, F
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma
2016-01-01 Belli, C; Piemonti, L; D'Incalci, M; Zucchetti, M; Porcu, L; Cappio, S; Doglioni, C; Allavena, P; Ceraulo, D; Maggiora, P; Dugnani, E; Cangi, Mg; Garassini, G; Reni, M
Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone
2006-01-01 Verschoyle, Re; Greaves, P; Cai, H; Arndt, B; Broggini, M; D'Incalci, M; Riccio, E; Doppalapudi, R; Kapetanovic, Im; Steward, Wp; Gescher, Aj
PREOPERATIVE DOXORUBICIN PLUS IFOSFAMIDE IN PRIMARY SOFT-TISSUE SARCOMAS OF THE EXTREMITIES
1993-01-01 Azzarelli, A; Quagliuolo, V; Casali, P; Fissi, S; Montalto, F; Santoro, A
Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
2015-01-01 Bulten, Bf; Verberne, Hj; Bellersen, L; Oyen, W; Sabate-Llobera, A; Mavinkurve-Groothuis, Amc; Kapusta, L; van Laarhoven, Hwm; de Geus-Oei, Lf
Targeting the EWS-FLI1 transcription factor in Ewing sarcoma
2015-01-01 Tancredi, R; Zambelli, A; Daprada, G A; Fregoni, V; Pavesi, L; Riccardi, A; Burdach, S; Grohar, P J; D'Incalci, M
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences
2010-01-01 Azzariti, A; Porcelli, L; Simone, Gm; Quatrale, Ae; Colabufo, Na; Berardi, F; Perrone, R; Zucchetti, M; D'Incalci, M; Xu, Jm; Paradiso, A
Unique features of trabectedin mechanism of action
2016-01-01 Larsen, Ak; Galmarini, Cm; D'Incalci, M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial | 1-gen-2016 | Krischke, M; Hempel, G; Voller, S; Andre, N; D'Incalci, M; Bisogno, G; Kopcke, W; Borowski, M; Herold, R; Boddy, Av; Boos, J | |
| Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph plus acute leukemias | 1-gen-2009 | Marangon, E; Citterio, M; Sala, F; Barisone, E; Lippi, Aa; Rizzari, C; Biondi, A; D'Incalci, M; Zucchetti, M | |
| Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib | 1-gen-2013 | Zucchetti, M; Bonezzi, K; Frapolli, R; Sala, F; Borsotti, P; Zangarini, M; Cvitkovic, E; Noel, K; Ubezio, P; Giavazzi, R; D'Incalci, M; Taraboletti, G | |
| The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma | 1-gen-2000 | Fumagalli, L; Zucchetti, M; Parisi, I; Viganò, M G; Zecca, B; Careddu, A; D'Incalci, M; Lazzarin, A | |
| Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243) | 1-gen-1999 | Sessa, C; Zucchetti, M; Ghielmini, M; Bauer, J; D'Incalci, M; de Jong, J; Naegele, H; Rossi, S; Pacciarini, Ma; Domenigoni, L; Cavalli, F | |
| Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma | 1-gen-2016 | Belli, C; Piemonti, L; D'Incalci, M; Zucchetti, M; Porcu, L; Cappio, S; Doglioni, C; Allavena, P; Ceraulo, D; Maggiora, P; Dugnani, E; Cangi, Mg; Garassini, G; Reni, M | |
| Preliminary safety evaluation of the putative cancer chemopreventive agent tricin, a naturally occurring flavone | 1-gen-2006 | Verschoyle, Re; Greaves, P; Cai, H; Arndt, B; Broggini, M; D'Incalci, M; Riccio, E; Doppalapudi, R; Kapetanovic, Im; Steward, Wp; Gescher, Aj | |
| PREOPERATIVE DOXORUBICIN PLUS IFOSFAMIDE IN PRIMARY SOFT-TISSUE SARCOMAS OF THE EXTREMITIES | 1-gen-1993 | Azzarelli, A; Quagliuolo, V; Casali, P; Fissi, S; Montalto, F; Santoro, A | |
| Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients | 1-gen-2015 | Bulten, Bf; Verberne, Hj; Bellersen, L; Oyen, W; Sabate-Llobera, A; Mavinkurve-Groothuis, Amc; Kapusta, L; van Laarhoven, Hwm; de Geus-Oei, Lf | |
| Targeting the EWS-FLI1 transcription factor in Ewing sarcoma | 1-gen-2015 | Tancredi, R; Zambelli, A; Daprada, G A; Fregoni, V; Pavesi, L; Riccardi, A; Burdach, S; Grohar, P J; D'Incalci, M | |
| Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences | 1-gen-2010 | Azzariti, A; Porcelli, L; Simone, Gm; Quatrale, Ae; Colabufo, Na; Berardi, F; Perrone, R; Zucchetti, M; D'Incalci, M; Xu, Jm; Paradiso, A | |
| Unique features of trabectedin mechanism of action | 1-gen-2016 | Larsen, Ak; Galmarini, Cm; D'Incalci, M |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile